KR20220062617A - 메토트렉세이트의 안과용 제형 - Google Patents

메토트렉세이트의 안과용 제형 Download PDF

Info

Publication number
KR20220062617A
KR20220062617A KR1020227012402A KR20227012402A KR20220062617A KR 20220062617 A KR20220062617 A KR 20220062617A KR 1020227012402 A KR1020227012402 A KR 1020227012402A KR 20227012402 A KR20227012402 A KR 20227012402A KR 20220062617 A KR20220062617 A KR 20220062617A
Authority
KR
South Korea
Prior art keywords
composition
mtx
administered
sio
tween
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227012402A
Other languages
English (en)
Korean (ko)
Inventor
딘 엘리엇
스티븐 기투 마차타
프라모드 사팟다
토마츠 스트리예프스키
Original Assignee
알데이라 테라퓨틱스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알데이라 테라퓨틱스, 아이엔씨. filed Critical 알데이라 테라퓨틱스, 아이엔씨.
Publication of KR20220062617A publication Critical patent/KR20220062617A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020227012402A 2019-09-13 2020-09-11 메토트렉세이트의 안과용 제형 Ceased KR20220062617A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900060P 2019-09-13 2019-09-13
US62/900,060 2019-09-13
US202063044288P 2020-06-25 2020-06-25
US63/044,288 2020-06-25
PCT/US2020/050565 WO2021051003A1 (en) 2019-09-13 2020-09-11 Ophthalmic formulations of methotrexate

Publications (1)

Publication Number Publication Date
KR20220062617A true KR20220062617A (ko) 2022-05-17

Family

ID=74866765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012402A Ceased KR20220062617A (ko) 2019-09-13 2020-09-11 메토트렉세이트의 안과용 제형

Country Status (9)

Country Link
US (2) US12005060B2 (https=)
EP (1) EP4028015A4 (https=)
JP (1) JP7682512B2 (https=)
KR (1) KR20220062617A (https=)
CN (1) CN114423432A (https=)
AU (1) AU2020344685A1 (https=)
CA (1) CA3149467A1 (https=)
IL (1) IL291228A (https=)
WO (1) WO2021051003A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP4028015A4 (en) 2019-09-13 2023-11-15 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253243A1 (en) 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005065079A2 (en) 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
CA2606226A1 (en) 2005-04-27 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for enhanced degradation of mutant proteins associated with human disease
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
WO2010047803A2 (en) 2008-10-22 2010-04-29 Oncotx, L.L.C. A method for the treatment of proliferative disorders of the eye
AU2010221438C1 (en) 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
GB201200192D0 (en) * 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
US20140105956A1 (en) 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
ES2969374T3 (es) * 2014-07-30 2024-05-17 Massachusetts Eye & Ear Infirmary Metotrexato para la vitreorretinopatía proliferativa
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
WO2018201146A1 (en) 2017-04-28 2018-11-01 Case Western Reserve University Compounds and methods of treating retinal degeneration
EP3759072A4 (en) 2018-03-01 2021-11-03 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM
EP4028015A4 (en) 2019-09-13 2023-11-15 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders

Also Published As

Publication number Publication date
EP4028015A4 (en) 2023-11-15
US20230018197A1 (en) 2023-01-19
AU2020344685A1 (en) 2022-04-14
US12005060B2 (en) 2024-06-11
US20220370460A1 (en) 2022-11-24
EP4028015A1 (en) 2022-07-20
IL291228A (en) 2022-05-01
JP2022548226A (ja) 2022-11-17
CN114423432A (zh) 2022-04-29
US12005061B2 (en) 2024-06-11
WO2021051003A1 (en) 2021-03-18
CA3149467A1 (en) 2021-03-18
JP7682512B2 (ja) 2025-05-26
US20230017743A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US12005060B2 (en) Ophthalmic formulations of methotrexate
JP6704400B2 (ja) 眼科用液剤
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
US9694003B2 (en) Formulations and methods for treating high intraocular pressure
CN116077665A (zh) 用于治疗眼科疾病和障碍的化合物
JP7397910B2 (ja) 一酸化窒素放出プロスタミドを含有する眼科用組成物
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
US20230190725A1 (en) Mek inhibitors for corneal scarring and neovascularization
KR20170088875A (ko) 수술 후 안구 염증성 병태를 억제시키기 위한 전방내용의, 항―염증성 및 산동성 용액
US20200206137A1 (en) Microparticle formulations for delivery of active agents
US12616699B2 (en) Ophthalmic formulations of methotrexate
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
HK40018890B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40092417A (zh) 用於治疗眼科疾病和障碍的化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601